Legato Capital Management LLC Grows Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Legato Capital Management LLC increased its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 52.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 217,318 shares of the company's stock after buying an additional 75,154 shares during the period. Legato Capital Management LLC owned 0.14% of Xeris Biopharma worth $1,193,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. NewEdge Advisors LLC acquired a new position in Xeris Biopharma during the 4th quarter valued at $34,000. Apella Capital LLC acquired a new position in Xeris Biopharma during the 1st quarter valued at $55,000. Xponance Inc. acquired a new position in Xeris Biopharma during the 1st quarter valued at $57,000. FNY Investment Advisers LLC acquired a new position in Xeris Biopharma during the 1st quarter valued at $63,000. Finally, Cibc World Markets Corp acquired a new position in Xeris Biopharma during the 4th quarter valued at $44,000. 42.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Oppenheimer lifted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Wall Street Zen downgraded shares of Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Xeris Biopharma has an average rating of "Moderate Buy" and a consensus target price of $6.25.

Xeris Biopharma Trading Down 2.9%

XERS stock traded down $0.15 during trading on Friday, hitting $5.02. The company had a trading volume of 1,076,262 shares, compared to its average volume of 2,441,839. The company has a fifty day moving average price of $4.82 and a two-hundred day moving average price of $4.41. The company has a market cap of $785.05 million, a P/E ratio of -16.73 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. On average, analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Insider Buying and Selling

In other Xeris Biopharma news, insider Kevin Mcculloch bought 25,000 shares of Xeris Biopharma stock in a transaction dated Friday, June 13th. The stock was bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the transaction, the insider owned 1,708,585 shares in the company, valued at $7,483,602.30. The trade was a 1.48% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.47% of the stock is currently owned by company insiders.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.